A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals

Antiviral Therapy

Volumn 1, Issue 4, 1996, Pages 255-263

  Weverling, Gerrit J ^a,b   Lange, Joep M A ^a   De Jong, Menno D ^a   De Weerd, Hellen ^a   Goudsmit, Jaap ^a   De Wolf, Frank ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; HIV-1; HUMANS; RNA, VIRAL; ZIDOVUDINE;

EID: 0030307909     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Annals of Internal Medicine 1993; 118:674-680.
2. Bass HZ, Hardy WD, Mitsuyasu RT, Taylor JM, Wang YX, Fischl MA, Spector SA, Richman DD & Fahey JL. The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. Journal of Acquired Immune Deficiency Syndromes 1992; 5:215-221.
3. DeGruttola V, Beckett LA, Coombs RW, Arduino JM, Balfour HH Jr, Rasheed S, Hollinger FB, Fischl MA & Volberding P for The AIDS Clinical Trials Group Virology Laboratories. Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Journal of Infectious Diseases 1994; 169:713-721.
4. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. Journal of Virology 1993; 67:1772-1777.
5. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM & Lifson JD. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259:1749-1754.
6. Mulder J, McKinney N, Christopherson C & Sninsky J. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. Journal of Clinical Microbiology 1994; 32:292-300.
7. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SJ, Stempien M, Hoo B, Besemer D, Yeghiazarian T, Irvine B, Kolberg J, Kokka R, Neuwald P & Urdea MS. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995; 8:446-454.
8. van Gemen B, van Beuningen R, Nabbe A, van Strijp D, Jurriaans S, Lens P & Kievits T. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. Journal of Virological Methods 1994; 49:157-167.
9. Moore RD, Creagh-Kirk T, Keruly J, Link G, Wang MC, Richman D & Chaisson RE for The Zidovudine Epidemiology Study Group. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Archives of Internal Medicine 1991; 151:981-986.
10. Katzenstein D, Hammer S, Hughes M, Gundacker H, Jackson B, Merigan T & C Hirsch M. Plasma virion RNA in response to early antiviral drug therapy in ACTG 175. Do changes in virus load parallel clinical and immunologic outcomes? 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 17-20 September 1995. Abstr. LB2.
11. Yerly S, Kaiser L, Mermillod B, Baumberger C, Hirschel B & Perrin L. Response of HIV RNA to didanosine as a predictive marker of survival. AIDS 1995; 9:159-163.
12. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA & Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
13. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiviral therapy for HIV infection in 1996. Journal of the American Medical Association 1996; 276:146-154.
14. Mulder JW, Cooper DA, Mathiesen L, Sandstrom E, Clumeck N, Gatell JM, French M, Donovan B, Gray F, Yeo JM & Lange JMA for The European-Australian Collaborative Group (Study 017). Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. AIDS 1994; 8:313-321.
15. Anonymous. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. Morbidity and Mortality Weekly Report 1987; 36(Suppl. 1):1S-15S.
16. Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, Koot M, Schuitemaker H & Goudsmit J. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994; 204:223-233.
17. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME & van der Noordaa J. A rapid and simple method for purification of nucleic acids. Journal of Clinical Microbiology 1990; 28:495-503.
18. Schuurman R, Descamps D, Weverling GJ, Kaye S, Tijnagel J, Williams I, Leeuwen Rv, Tedder R, Boucher CAB, Brun-Vezinet F & Loveday C. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. Journal of Clinical Microbiology 1996; 34:3016-3022.
19. Boucher CAB, Lange JM, Miedema FF, Weverling GJ, Koot M, Mulder JW, Goudsmit J, Kellam P, Larder BA & Tersmette M. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992; 6:1259-1264.
20. + cell depletion and progression to AIDS. Annals of Internal Medicine 1993; 118:681-688.
21. Koot M, Schellekens PT, Mulder JW, Lange JM, Roos MT, Coutinho RA, Tersmette M & Miedema F. Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. Journal of Infections Diseases 1993; 168:733-736.
22. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP & Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of Internal Medicine 1995; 122:573-579.
23. + lymphocyte counts and the risk of progression to AIDS. New England Journal of Medicine 1996; 334:426-431.
24. Brambilla D, Yen-Lieberman B, Jackson B, Bremer J, Coombs R, Lin HJ, Katzenstein D, Palumbo P, Rasheed S & Reichelderfer P. Variation in estimates of HIV-1 plasma RNA concentration among laboratories and assay kits. 3rd Conference on Retroviruses and Opportunistic Infections, Washington DC, USA, 28 January - 3 February 1996. Abstr. 550.
25. Bruisten SM, Koppelman MH, Roos MT, Loeliger AE, Reiss P, Boucher CAB & Huisman HG. Use of competitive polymerase chain reaction to determine HIV-1 levels in response to antiviral treatments. AIDS 1993; 7(Suppl. 2):S15-S20.
26. Schuitemaker H, Koot M & Miedema F. Recent development on research in AIDS pathogenesis. Vox Sanguinis 1994; 67(Suppl. 3):133-136.